home > investor relations

Highlights

Interim Results 2011

Financial Highlights

Revenues up 43%* to £3.54m (H1 2010: £2.48m)
US site revenues grow to £1.27 million
Over 12% revenue growth in our UK operations excluding the loss of the Company’s largest customer due to their facility closures
Reliance on individual large customers has been reduced, dropping from 22% in 2009, to 16% in 2010, to an expected 11% in 2011
Cash generation increased with EBITDA of £261,000 (H1 2010: £166,000)
Continuing profitability with operating profit of £23,000 (H1 2010: £54,000)
Cash generated from operations at £91,000 (H1 2010: £237,000)
Growth of new customer base continues into second half of 2011

* Including acquisitions

Steve Harris, Chairman of Cyprotex PLC, said:

“We have delivered a 43% increase in revenues and a seventh consecutive period of profitability despite a tough industry and macro-economic environment. The acquisition of Apredica and our new business efforts have helped drive this growth which more than offset the unexpected loss of our largest customer. We are focused on continuing to drive revenues in the traditionally stronger second half whilst continuing to explore potential bolt on acquisitions in a highly fragmented market.”

Download Interim Results for the Six Months to 30 June 2011

Download Annual Report & Accounts 2010


October 4, 2011 Cyprotex Launches Breakthrough Genomic ADME Service (gADME™)
September 29, 2011 Board Change
August 25, 2011 Interim Results

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100